Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2006-06-23
2009-10-27
Nickol, Gary B (Department: 1648)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Reexamination Certificate
active
07608688
ABSTRACT:
The present invention relates to HIV-1 envelope proteins from a donor with non-progressive HIV-1 infection whose serum contains broadly cross-reactive, primary virus neutralizing antibody. The invention also relates to isolated or purified proteins and protein fragments that share certain amino acids at particular positions with the foregoing HIV-1 proteins.
REFERENCES:
patent: 4943627 (1990-07-01), Gilbert et al.
patent: 5019387 (1991-05-01), Haynes et al.
patent: 5439809 (1995-08-01), Haynes et al.
patent: 5459060 (1995-10-01), Cotropia
patent: 5622933 (1997-04-01), Sabatier et al.
patent: 5756674 (1998-05-01), Katinger et al.
patent: 5854400 (1998-12-01), Chang et al.
patent: 5993819 (1999-11-01), Haynes et al.
patent: 0471407 (1992-02-01), None
patent: WO 92/20373 (1992-11-01), None
patent: WO 93/05812 (1993-04-01), None
Cotropia et al. (1996) A human monoclonal antibody to HIV-1 gp41 with neutralizing activity against diverse laboratory isolates, J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 12:221-232.
Douglas et al. (1996) An efficient method for the rescue and analysis of functional HIV-1 env genes: evidence for recombination in the vicinity of the tat/rev splice site, AIDS 10:39-46.
Hioe et al. (1997) Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies, Int. Immunol. 9:1281-1290.
Kelleher et al. (1997) AIDS Research and Human Retroviruses 13(1): 29-32.
Klein et al. (2002) Clinical Therapeutics 22(3): 295-314.
Korber et al. (2001) British Medical Bulletin 58: 19-42.
Lukashov et al. (1996) AIDS Research and Human Retroviruses 12(10): 951-953.
Moore et al. (1993) Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: Human immune response to the V1 and V2 domains, J. Virol. 67:6136-6151.
Muster et al. (1993) A conserved neutralization epitope on gp41 of human immunodeficiency virus type 1, J. Virol. 67:6642-6647.
Purtscher et al. (1994) A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1, AIDS Res. Hum. Retroviruses 10:1651-1658.
Sabri et al. (1996) Lack of correlation between V3 amino acid sequence and syncytium-inducing capacity of some HIV type 1 isolates, AIDS Res. Hum. Retroviruses, 12:855.
Sala et al. (1994). Journal of Virology. 68 (8): 5280-5283.
Sequence alignment of SEQ ID No. 1 with Lukashov et. al. SPTREMBL—17 datatbase; Accession No. Q69692; 1996 from AIDS Research and Human Retroviruses; 12: 951-953.
Sequence alignment of SEQ ID No. 24 with SPTREMBL database accession No. Q71538 submitted Nov. 1, by Strunnikova et al.
Sequence alignment of SEQ ID No. 1 with Sala et al. SPTREMBL—17; Accession No. Q78039; Nov. 1996; from J. Virol. 68: 5280-5283.
Sequence alignment of SEQ ID No. 24 with geneseq database accession No. AAR77770, submitted Sep. 1995 in WO 94/229339-A1.
Sequence alignment of the V3 region of SEQ ID No. 1 to Geneseq data accession No. AAR20883, submitted Jun. 1, 1992 in EP471407-A of Lewis et al.
Thali et al. (1993) Characterization of conserved human immunodeficiency virus type-1 gp120 neutralization epitopes exposed upon gp120-CD4, J. Virol. 67:3978-3988.
Thali et al. (1994) Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type-1 gp120 glycoprotein conferred by a gp41 amino acid change, J. Virol. 68:674-680.
Trkola et al. (1995) Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG, J. Virol. 69:6609-6617.
Trkola et al. (1996) Human monoclonal antibody 2G12 defines a distinctive neutralization epitope of human immunodeficiency virus type-1, J. Virol. 70:1100-1108.
VanCott et al. (1997) Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type-1 isolates elicited by immunization with oligomeric gp160, J. Virol. 71:4319-4330.
XP002220280, EBI database accession No. O71260, Database EMBL Online, (1998).
XP002220281, EBI database accession No. P88523, Database EMBL Online, (1997).
XP002220282, EBI database accession No. Q73297, Database EMBL Online, (1996).
Zwart et al. (1991) Immunodominance and antigenic variation of the principal neutralization domain of HIV-1, J. Virol. 181:481-489.
Akerblom et al. (1990) Neutralizing cross-reactive and non-neutralizing monoclonal antibodies to HIV-1 gp120, AIDS 4: 953-60 (Abstract Only).
MacGregor et al. (1998) First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response, J. Infect. Dis. 178: 92-100 (Abstract Only).
Nakamura et al. (1992) Monoclonal Antibodies to the extracellular domain of HIV-1 IIIB gp160 that neutralize infectivity, block binding to CD4, and react with diverse isolates, AIDS Res Hum Retroviruses 8: 1875-85 (Abstract Only).
Wagner et al. (1992) Immunological reactivity of human immunodeficiency virus type I derived peptide representing a consensus sequence of the gp120 major neutralizing region V3, Arch. Virol. 127: 139-52 (Abstract only).
Quinnan, Jr. Gerald V.
Zhang Peng Fei
Kinsey White Nicole
Morgan & Lewis & Bockius, LLP
Nickol Gary B
The Henry M. Jackson Foundation for the Advancement of Military
LandOfFree
HIV-1 protein associated with broadly reactive neutralizing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with HIV-1 protein associated with broadly reactive neutralizing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HIV-1 protein associated with broadly reactive neutralizing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4054930